3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
Gastrointestinal
1
Conditions
Breast Neoplasms
76
Neoplasm Metastasis
12
Neoplasms
8
Ovarian Neoplasms
6
Endometrial Neoplasms
6
Pancreatic Neoplasms
5
Carcinoma, Renal Cell
5
Sarcoma
4
Neoplasms by Site
4
Lymphoma, Non-Hodgkin
4
Breast Diseases
4
Squamous Cell Carcinoma of Head and Neck
3
Multiple Myeloma
3
Lymphoma
3
Lung Neoplasms
3
Liposarcoma
3
Kidney Neoplasms
3
Head and Neck Neoplasms
3
Glioma
3
Wilms Tumor
2
Uterine Cervical Neoplasms
2
Triple Negative Breast Neoplasms
2
Sarcoma, Ewing
2
Rhabdomyosarcoma
2
Rhabdoid Tumor
2
Recurrence
2
Prostatic Neoplasms
2
Precursor Cell Lymphoblastic Leukemia-Lymphoma
2
Osteosarcoma
2
Neuroectodermal Tumors, Primitive, Peripheral
2
Interventions
Imatinib Mesylate
12
Sunitinib
10
ripretinib
5
regorafenib
4
Blood Specimen Collection
3
envafolimab
2
Specimen Handling
2
Paclitaxel
2
Magnetic Resonance Spectroscopy
2
IDRX-42
2
Biopsy
2
trastuzumab deruxtecan
1
spartalizumab
1
ribociclib
1
pemigatinib
1
palbociclib
1
olverembatinib
1
nilotinib
1
guadecitabine
1
binimetinib
1
avelumab
1
avapritinib
1
atezolizumab
1
apatinib
1
Temozolomide
1
TAS-116
1
Surgical Instruments
1
Sorafenib
1
Rogaratinib
1
Nivolumab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Gastrointestinal Stromal Tumors
×
palbociclib
×
1 year
×
Clear all
NCT01907607
2025-08-24
CYCLIGIST
Institut Bergonié
Phase 2
Completed
29 enrolled
8 charts